A novel cancer immunotherapy shows early promise in preclinical studies – Science Daily
|
A novel cancer immunotherapy shows early promise in preclinical studies
Science Daily However, 4D3 combined with cyclophosphamide chemotherapy curbed both primary tumor growth and metastasis. This means that combination immunotherapy with GARP antibody might boost the effectiveness of standard chemotherapy in breast cancer. |
